Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2007

View Archived Issues

Recent patents describe new antidiabetic agents

Novel therapeutic options for obesity described in recent patent literature

Recent patents disclose novel antiinfective agents

Varenicline shows promise in preclinical models of alcohol dependence

CVBT-141F successfully completes preclinical stroke research

Pediatric phase II clinical trial of Intercell's JE vaccine begins in India

Opko Health initiates phase III trial of bevasiranib in wet AMD

Ghrelin receptor: Target To Watch for development of therapeutics for severe gastroparesis

Plethora secures funds for development of Invicorp for treatment of ED

Enrollment in Angiotech's CVC pivotal study completed

FDA approves initiation of phase III trials for Protalix's prGCD

Enrollment for CSL's phase III trial of subcutaneous immunoglobulin completed

H5N1 influenza antigen delivered to DelSite

Uluru and ImmuneRegen to codevelop wound care therapeutic

Update on Antisoma's phase II trial of ASA-404 for ovarian cancer

Positive results for Vernalis' phase IIa trial of V-3381 for neuropathic pain

YM reports secondary findings of phase IIb trial of AeroLEF for pain

FDA approves GeneSearch Breast Lymph Node Assay

Extina Foam approved for seborrheic dermatitis

First launch for Torisel

Ceftobiprole submissions accepted for review in U.S. and E.U.

Priority review for Abilify in treatment of major depressive disorder

VX-765 demonstrates antiseizure activity in animals

Studies reveal activity, pharmacokinetics of the antiepileptic eslicarbazepine

Studies profile lacosamide in epilepsy

Nerviano presents first Cdc7 kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...